[go: up one dir, main page]

CL2012000469A1 - Composición farmacéutica que comprende un compuesto conjugado de insulina de absorcion lenta; un envase; una suspensión que comprende la composición y su método de preparación; su uso para el tratamiento o prevención de una patología asociado a deficiencia de insulina, como diabetes; un kit. - Google Patents

Composición farmacéutica que comprende un compuesto conjugado de insulina de absorcion lenta; un envase; una suspensión que comprende la composición y su método de preparación; su uso para el tratamiento o prevención de una patología asociado a deficiencia de insulina, como diabetes; un kit.

Info

Publication number
CL2012000469A1
CL2012000469A1 CL2012000469A CL2012000469A CL2012000469A1 CL 2012000469 A1 CL2012000469 A1 CL 2012000469A1 CL 2012000469 A CL2012000469 A CL 2012000469A CL 2012000469 A CL2012000469 A CL 2012000469A CL 2012000469 A1 CL2012000469 A1 CL 2012000469A1
Authority
CL
Chile
Prior art keywords
composition
insulin
diabetes
kit
prevention
Prior art date
Application number
CL2012000469A
Other languages
English (en)
Inventor
Harald Rau
Felix Cleemann
Thomas Wegge
Kennett Sprogoe
Ulrich Harsel
Vagt Silvia Kaden
Torben Lebmann
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of CL2012000469A1 publication Critical patent/CL2012000469A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composición farmacéutica que comprende un compuesto de insulina que mantiene un nivel plasmático durante por lo menos 3 días; un envase; una suspensión que comprende la composición y su método de preparación; su uso para el tratamiento o prevención de una patología asociado a deficiencia de insulina, como diabetes; un kit.
CL2012000469A 2009-07-31 2012-02-23 Composición farmacéutica que comprende un compuesto conjugado de insulina de absorcion lenta; un envase; una suspensión que comprende la composición y su método de preparación; su uso para el tratamiento o prevención de una patología asociado a deficiencia de insulina, como diabetes; un kit. CL2012000469A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09167017 2009-07-31
EP09179337 2009-12-15
EP09179827 2009-12-18

Publications (1)

Publication Number Publication Date
CL2012000469A1 true CL2012000469A1 (es) 2012-10-19

Family

ID=43033453

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000469A CL2012000469A1 (es) 2009-07-31 2012-02-23 Composición farmacéutica que comprende un compuesto conjugado de insulina de absorcion lenta; un envase; una suspensión que comprende la composición y su método de preparación; su uso para el tratamiento o prevención de una patología asociado a deficiencia de insulina, como diabetes; un kit.

Country Status (29)

Country Link
US (1) US9265723B2 (es)
EP (1) EP2459171B1 (es)
JP (1) JP5732053B2 (es)
KR (1) KR101759499B1 (es)
CN (1) CN102625695B (es)
AU (1) AU2010277560B2 (es)
BR (1) BR112012001988A2 (es)
CA (1) CA2769540C (es)
CL (1) CL2012000469A1 (es)
CO (1) CO6491085A2 (es)
CR (1) CR20120019A (es)
DK (1) DK2459171T3 (es)
EC (1) ECSP12011631A (es)
ES (1) ES2636741T3 (es)
GT (1) GT201200020A (es)
IL (1) IL217613A (es)
MA (1) MA33466B1 (es)
MX (1) MX2012001141A (es)
NI (1) NI201200013A (es)
NZ (1) NZ597964A (es)
PE (1) PE20121170A1 (es)
PL (1) PL2459171T3 (es)
PT (1) PT2459171T (es)
RU (1) RU2556340C2 (es)
SG (1) SG178195A1 (es)
TN (1) TN2012000010A1 (es)
UA (1) UA108475C2 (es)
WO (1) WO2011012719A1 (es)
ZA (1) ZA201200224B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005099768A2 (en) * 2004-03-23 2005-10-27 Complex Biosystems Gmbh Polymeric prodrug with a self-immolative linker
US9526764B2 (en) 2008-10-17 2016-12-27 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1-agonist
PL2459171T3 (pl) 2009-07-31 2017-11-30 Sanofi-Aventis Deutschland Gmbh Kompozycja insuliny o długim działaniu
PE20120918A1 (es) 2009-07-31 2012-08-14 Sanofi Aventis Deutschland Profarmacos que comprenden un conjugado de insulina-conector
HUE038147T2 (hu) 2009-11-13 2018-09-28 Sanofi Aventis Deutschland GLP-1 agonistát, inzulint és metionint tartalmazó gyógyászati készítmény
WO2011058082A1 (de) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Pharmazeutische zusammensetzung umfassend einen glp-1-agonisten und methionin
AU2012216648C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
WO2012028172A1 (en) 2010-08-30 2012-03-08 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
EP2785367A4 (en) * 2011-11-28 2015-06-17 Phasebio Pharmaceuticals Inc THERAPEUTIC AGENTS COMPRISING AMINO ACID SEQUENCES OF INSULIN
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
US12239822B2 (en) 2013-03-15 2025-03-04 Windgap Medical, Inc. Portable drug mixing and delivery device and associated methods
HUE042381T2 (hu) 2013-04-03 2019-06-28 Sanofi Sa Cukorbetegség kezelése hosszan ható inzulinkészítményekkel
CA2934538C (en) 2013-12-18 2023-03-14 Windgap Medical, Inc. Drug mixing and delivery system and method
TW201609145A (zh) * 2013-12-25 2016-03-16 參天製藥股份有限公司 注射劑及形成緩釋（ｄｅｐｏｔ）之方法
JP6641280B2 (ja) * 2014-01-09 2020-02-05 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤
CA2932875A1 (en) * 2014-01-09 2015-07-16 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
JP2020143105A (ja) * 2014-01-09 2020-09-10 サノフイＳａｎｏｆｉ インスリンアスパルトの安定化された医薬製剤
WO2015104310A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized pharmaceutical formulations of insulin aspart
JP2020114861A (ja) * 2014-01-09 2020-07-30 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の、グリセリンを含まない安定化された医薬製剤
JP7173953B2 (ja) * 2014-01-09 2022-11-16 サノフイ インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤
AR099569A1 (es) * 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
CN103830189A (zh) * 2014-03-04 2014-06-04 山东新时代药业有限公司 一种重组甘精胰岛素制剂及其制备方法
EP3220961B1 (en) 2014-10-22 2023-07-05 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
HRP20230470T1 (hr) 2014-12-12 2023-07-21 Sanofi-Aventis Deutschland Gmbh Formulacija fiksnog omjera inzulin glargin/liksisenatid
WO2016100949A2 (en) 2014-12-18 2016-06-23 Windgap Medical, Inc. Method and compositions for dissolving or solubilizing therapeutic agents
CN105796508A (zh) * 2014-12-30 2016-07-27 江苏万邦生化医药股份有限公司 甘精胰岛素缓释微球、甘精胰岛素微球注射剂及其制备方法
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
HRP20241591T1 (hr) 2016-03-01 2025-02-28 Ascendis Pharma Bone Diseases A/S Pth predlijekovi
WO2018057977A1 (en) 2016-09-23 2018-03-29 Delpor, Inc. Stable compositions for incretin mimetic compounds
US11590207B2 (en) * 2016-09-29 2023-02-28 Ascendis Pharma Bone Diseases A/S Dosage regimen for a controlled-release PTH compound
BR112019005793A2 (pt) 2016-09-29 2019-06-18 Ascendis Pharma Bone Diseases As compostos de pth com baixas proporções de pico-para-vale
US10869851B1 (en) * 2017-03-13 2020-12-22 The United States Government As Represented By The Secretary Of The Army Targeting NUR77 for mitigating perinatal neuroinflammation
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
CN118903385A (zh) 2017-08-24 2024-11-08 诺和诺德股份有限公司 Glp-1组合物及其用途
US20220040099A1 (en) * 2017-12-06 2022-02-10 Adocia Injectable solution at ph 7 comprising at least a basal insulin which pi is comprised between 5.8 and 8.5 and a copolyamino acid bearing carboxylate charges and hydrophobic radicals
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
KR20220066056A (ko) 2019-08-16 2022-05-23 어플라이드 몰레큘라 트랜스포트 인크. 조성물, 제형, 및 인터루킨 제조 및 정제
PE20230819A1 (es) 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1
KR20230047259A (ko) * 2021-09-30 2023-04-07 주식회사 엘지화학 마이크로 캐리어, 세포 복합체 및 이를 포함하는 의료용 조성물, 미용 조성물, 의료 용품 및 미용 용품
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK257988D0 (da) 1988-05-11 1988-05-11 Novo Industri As Nye peptider
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
PT93057B (pt) 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
DK155690D0 (da) 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
US5634943A (en) 1990-07-12 1997-06-03 University Of Miami Injectable polyethylene oxide gel implant and method for production
EP0627911B1 (en) 1992-02-28 2000-10-25 Board Of Regents The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5514379A (en) 1992-08-07 1996-05-07 The General Hospital Corporation Hydrogel compositions and methods of use
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
DE19626762A1 (de) 1996-07-03 1998-01-08 Basf Ag Enzymatisch spaltbare Linker für Festphasensynthesen
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
AU757748B2 (en) 1997-11-14 2003-03-06 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
DK1032587T4 (da) 1997-11-14 2013-04-08 Amylin Pharmaceuticals Llc Hidtil ukendte exendinagonist-forbindelser
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
EP1037649B1 (en) 1997-12-17 2009-09-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
CA2316834C (en) 1998-01-07 2006-01-03 Shearwater Polymers, Inc. Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom
DE69936446T2 (de) 1998-02-13 2008-03-06 Amylin Pharmaceuticals, Inc., San Diego Inotropische und diuretische effekte von exendin und glp-1
WO2000021572A2 (en) 1998-10-09 2000-04-20 The University Of Michigan Hydrogels and water soluble polymeric carriers for drug delivery
EP1137373A4 (en) 1998-12-04 2004-05-19 Chandrashekhar P Pathak BIOCOMPATIBLE, CROSSLINKED POLYMERS
US7744912B1 (en) 1999-02-01 2010-06-29 Eidgenossische Technische Hochschule Zurich Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups
DE60026300T2 (de) 1999-05-17 2006-11-16 Conjuchem, Inc., Montreal Schutz endogener, therapeutisch aktiver peptide vor peptidaseaktivität durch konjugation an blutbestandteile
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
CA2376714A1 (en) 1999-06-11 2001-01-04 Shearwater Corporation Hydrogels derived from chitosan and poly(ethylene glycol) or related polymers
US6372813B1 (en) 1999-06-25 2002-04-16 Motorola Methods and compositions for attachment of biomolecules to solid supports, hydrogels, and hydrogel arrays
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
CA2398788A1 (en) 2000-01-28 2001-08-02 Infimed Therapeutics, Inc. Slow release protein polymers
US6884778B2 (en) 2000-04-14 2005-04-26 William Marsh Rice University Biocompatible macromers
US7291673B2 (en) 2000-06-02 2007-11-06 Eidgenossiche Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
JP4841066B2 (ja) 2000-09-01 2011-12-21 ライスユニバーシティ 酸化窒素生成ヒドロゲル物質
US6537569B2 (en) 2001-02-14 2003-03-25 Microvention, Inc. Radiation cross-linked hydrogels
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
WO2002085419A2 (en) 2001-04-23 2002-10-31 Wisconsin Alumni Research Foundation Bifunctional-modified hydrogels
CA2447236A1 (en) 2001-05-21 2002-11-28 Nektar Therapeutics Pulmonary administration of chemically modified insulin
DE60132094T3 (de) 2001-10-26 2012-02-02 Octoplus Polyactive Sciences B.V. Verfahren zur Herstellung von gereinigten Partikeln
US6960298B2 (en) 2001-12-10 2005-11-01 Nanogen, Inc. Mesoporous permeation layers for use on active electronic matrix devices
US7247609B2 (en) 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
CA2479810A1 (en) 2002-04-04 2003-10-16 Enzon, Inc. Polymeric acyl derivatives of indoles
DE10221457A1 (de) 2002-05-15 2003-11-27 Behr Gmbh & Co Wärmeübertrager und Verfahren zu seiner Herstellung
JP2005535604A (ja) 2002-06-03 2005-11-24 アルニス バイオサイエンシーズ， インコーポレイテッド 治療剤を含むポリマーナノ物品
JP2005528913A (ja) 2002-06-10 2005-09-29 メルク　エンド　カムパニー　インコーポレーテッド 新規動原体関連モータータンパク質をコードする単離核酸分子及びその使用
US7087229B2 (en) 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
EP1560599A1 (en) 2002-11-14 2005-08-10 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
AU2004228793B2 (en) 2003-04-08 2009-10-08 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
JP5048332B2 (ja) 2003-05-23 2012-10-17 ネクター セラピューティクス 特定の原子配置を有するポリマー誘導体
EP1525890A1 (en) 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophore complexes
WO2005099768A2 (en) 2004-03-23 2005-10-27 Complex Biosystems Gmbh Polymeric prodrug with a self-immolative linker
EP1586334A1 (en) 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugates with peg
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
WO2006038462A1 (ja) 2004-10-01 2006-04-13 Kyushu University, National University Corporation 新規ステロイド産生細胞
DE102004051715A1 (de) 2004-10-23 2005-06-30 Clariant Gmbh Flüssigwaschmittel enthaltend Farbfixiermittel
US7678551B2 (en) 2004-10-25 2010-03-16 Seradyn, Inc. Immunoassays for lamotrigine
US20060115865A1 (en) 2004-10-25 2006-06-01 Anlong Ouyang Lamotrigine analogs
US7407117B2 (en) 2004-10-28 2008-08-05 Meadwestvaco Calmar, Inc. Liquid sprayer assembly
JP2006163996A (ja) 2004-12-09 2006-06-22 Evolium Sas 行動履歴に基づくプッシュ型の情報提供システム
JP2008526846A (ja) 2005-01-05 2008-07-24 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 鎮痛性結合体
KR100665672B1 (ko) 2005-04-13 2007-01-09 성균관대학교산학협력단 새로운 온도 및 ｐＨ 민감성 블록 공중합체 및 이를 이용한고분자 하이드로겔
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
WO2007053946A1 (en) 2005-11-09 2007-05-18 Conjuchem Biotechnologies Inc. Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin
CA2636957A1 (en) 2006-01-12 2007-07-19 Histogenics Corporation Method for repair and reconstruction of ruptured ligaments or tendons and for treatment of ligament and tendon injuries
DE602006007679D1 (de) 2006-03-31 2009-08-20 Sony Deutschland Gmbh Verfahren zur Herstellung eines vernetzten Polymer-Gels
EP2021094A4 (en) 2006-05-25 2010-02-10 Gen Hospital Corp NON-CROSSLINKING AGENTS AND METHODS FOR BLOCKING CROSSLINKAGE OF INJECTABLE HYDROGEL PREPARATIONS
ES2542146T3 (es) 2006-07-31 2015-07-31 Novo Nordisk A/S Insulinas extendidas PEGiladas.
JP2010503707A (ja) 2006-09-15 2010-02-04 エンゾン ファーマスーティカルズ インコーポレイテッド オリゴヌクレオチドの送達を目的としたヒンダードエステル系生体分解性リンカー
GB0619175D0 (en) 2006-09-29 2006-11-08 Univ Nottingham Polymer
WO2008066787A2 (en) 2006-11-27 2008-06-05 E. I. Du Pont De Nemours And Company Multi-functional polyalkylene oxides, hydrogels and tissue adhesives
EP2121057A4 (en) 2007-02-06 2012-10-10 Incept Llc POLYMERIZATION WITH PRECIPITATION OF PROTEINS FOR ELUTION IN A PHYSIOLOGICAL SOLUTION
US20080220047A1 (en) 2007-03-05 2008-09-11 Sawhney Amarpreet S Low-swelling biocompatible hydrogels
WO2008116913A2 (en) 2007-03-28 2008-10-02 Novo Nordisk A/S Peptide compounds with transient biodegradable pegylation
WO2008125655A1 (en) 2007-04-13 2008-10-23 Kuros Biosurgery Ag Polymeric tissue sealant
US20100120660A1 (en) * 2007-04-30 2010-05-13 Per Balschmidt Highly concentrated insulin solutions and compositions
WO2008148839A2 (en) 2007-06-08 2008-12-11 Ascendis Pharma As Long-acting polymeric prodrugs of exendin
WO2009010428A1 (en) * 2007-07-16 2009-01-22 Novo Nordisk A/S Protease stabilized, pegylated insulin analogues
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
BRPI0906643A2 (pt) 2008-02-01 2019-09-10 Ascendis Pharma As profármaco compreendendo um conjugado fármaco-ligante
US8410189B2 (en) 2008-02-13 2013-04-02 Hyperbranch Medical Technology, Inc. Crosslinked polyalkyleneimine hydrogels with tunable degradation rates
EP2273880B1 (en) 2008-04-28 2014-12-31 Zogenix, Inc. Novel formulations for treatment of migraine
HUE029926T2 (en) 2008-04-29 2017-04-28 Ascendis Pharma Growth Disorders Div As Pegylated recombinant human growth hormone compounds
EP2403537A1 (en) 2009-03-05 2012-01-11 Ascendis Pharma A/S Interferon alpha carrier prodrugs
HUE052816T2 (hu) 2009-07-31 2021-05-28 Ascendis Pharma As Biológiailag lebontható polietilénglikol bázisú vízoldható hidrogélek
PL2459171T3 (pl) 2009-07-31 2017-11-30 Sanofi-Aventis Deutschland Gmbh Kompozycja insuliny o długim działaniu
PE20120918A1 (es) 2009-07-31 2012-08-14 Sanofi Aventis Deutschland Profarmacos que comprenden un conjugado de insulina-conector
RU2558847C9 (ru) 2009-10-29 2016-07-20 Асцендис Фарма Ас Стерилизация биоразлагаемых гидрогелей
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate

Also Published As

Publication number Publication date
AU2010277560B2 (en) 2014-12-11
RU2556340C2 (ru) 2015-07-10
CO6491085A2 (es) 2012-07-31
KR20120089261A (ko) 2012-08-09
US9265723B2 (en) 2016-02-23
CR20120019A (es) 2012-03-02
ECSP12011631A (es) 2012-02-29
PE20121170A1 (es) 2012-09-10
AU2010277560A1 (en) 2012-02-23
NI201200013A (es) 2012-05-29
CA2769540A1 (en) 2011-02-03
DK2459171T3 (en) 2017-09-25
EP2459171A1 (en) 2012-06-06
SG178195A1 (en) 2012-03-29
CA2769540C (en) 2017-08-15
MX2012001141A (es) 2012-03-29
GT201200020A (es) 2014-09-10
US20120183616A1 (en) 2012-07-19
NZ597964A (en) 2014-04-30
WO2011012719A1 (en) 2011-02-03
KR101759499B1 (ko) 2017-07-19
ZA201200224B (en) 2012-09-26
TN2012000010A1 (en) 2013-09-19
EP2459171B1 (en) 2017-06-21
CN102625695B (zh) 2015-05-27
CN102625695A (zh) 2012-08-01
PL2459171T3 (pl) 2017-11-30
UA108475C2 (uk) 2015-05-12
BR112012001988A2 (pt) 2017-05-09
ES2636741T3 (es) 2017-10-09
RU2012107487A (ru) 2013-09-10
JP2013500952A (ja) 2013-01-10
JP5732053B2 (ja) 2015-06-10
MA33466B1 (fr) 2012-07-03
PT2459171T (pt) 2017-08-16
IL217613A (en) 2016-08-31

Similar Documents

Publication Publication Date Title
CL2012000469A1 (es) Composición farmacéutica que comprende un compuesto conjugado de insulina de absorcion lenta; un envase; una suspensión que comprende la composición y su método de preparación; su uso para el tratamiento o prevención de una patología asociado a deficiencia de insulina, como diabetes; un kit.
CY1120389T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει εναν glp-1-αγωνιστη, μια ινσουλινη και μεθειονινη
CL2012000248A1 (es) Compuesto conjugado de insulina; procedimiento de preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; kit farmaceutico; uso en el tratamiento de trastornos mediados por insulina.
CL2013002171A1 (es) Composicion fungicida y bactericida que comprende compuestos organicos volatiles de origen natural; uso de la composición.
CL2012003026A1 (es) Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad.
CL2013001964A1 (es) Compuestos derivados de heterociclos, como inhibidores de bace 1 o 2; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento o prevencion de la enfermedad de alzheimer o deterioro cognitivo leve, resistencia a la insulina, diabetes tipo 2, entre otras.
CL2008001821A1 (es) Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras.
CL2011000527A1 (es) Compuestos derivados de benzofurano; composicion farmaceutica que los comprende;y su uso en el tratamiento de la hepatitis c.
CL2007003033A1 (es) Compuestos derivados de benzoilamino heterociclos; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la diabetes tipo ii.
CL2011003350A1 (es) Compuestos derivados de heterociclo nitrogenados, moduladores pkm2; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
CL2007002682A1 (es) Compuestos derivados de 4-metilpiridopirimidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el crecimiento anormal de celulas, como cancer.
CL2011002548A1 (es) Compuestos derivados de resolviina; composicion farmaceutica; uso de la composicion; kit farmaceutico; combinacion farmaceutica; uso de los compuestos en el tratamiento y/o prevencion de una condicion oftalmica.
CL2008000691A1 (es) Compuestos derivados de dihidro y tetrahidro oxazolopirimidinonas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la esquizofrenia, epilepsia, entre otras enfermedades.
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
CL2008001560A1 (es) Compuestos derivados de heterociclo de nitrogenado, moduladores de gamma secretasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas como el alzheimer, sindrome de down; kit farmaceutico.
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
CL2007003138A1 (es) Compuestos derivados de anilinopiperazina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2009000173A1 (es) Compuestos derivados de urea-tetrahidroxiquinoxalina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento y la prevencion de la obesidad y la diabetes, resistencia a la insulina, sindrome metabolico, entre otros.
CL2013001104A1 (es) Composicion farmaceutica que comprende un inhibidor de sglt2 y una insulina; y uso para tratar una enfermedad o afeccion tal como diabetes mellitus, diabetes mellitus tipo 1 y 2, entre otras.
CL2009000309A1 (es) Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2.
CL2012001321A1 (es) Compuestos derivados de espiro inden (o indan) - 1,4-piperidin o espiro indolin - 3,4-piperidin, activadores gpr40; composicion farmaceutica que los comprende; y su uso en el tratamiento de la diabetes.
EA201200484A1 (ru) Фармацевтическая композиция с действующими веществами - метформином и ситаглиптином или вилдаглиптином
CL2011000043A1 (es) Compuestos derivados de benzoazepina sustituidos; compuestosintermediarios; metodo de sintesis; composicion farmaceutica; y uso en el tratamiento o prevencion de un trastorno del sistema nervioso central.
GT201000047A (es) Mejoras en compuestos organicos o relacionadas con los mismos
CL2008002049A1 (es) Compuestos derivados de aminoindol macrociclicos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.